Renal Cell Carcinoma: Natural History and Results of Treatment

Patel, Natvarlal P.; Lavengood, Russell W.

doi:10.1016/s0022-5347(17)57611-9

Cited by 172 publications

(49 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prior to the introduction of immunotherapy, the prognosis of patients with metastatic renal carcinoma was dismal, with reported 1-year survival rates of 26% and 3-year survival rates of 4%. 14 In these circumstances, nephrectomy added little to patient management, and there was general agreement that surgery was indicated only for symptom palliation for patients with a good performance status. [15][16][17] An exception to this practice was for patients with a solitary metastasis in whom prolonged survival can occur following a combination of nephrectomy and surgical resection of the metastasis.…”

Section: Rationale For and Contribution Of Nephrectomy To Immunotherapymentioning

confidence: 99%

Immunotherapy of Metastatic Renal Cell Cancer

Fishman

Seigne

2002

Cancer Control

View full text Add to dashboard Cite

Section: Rationale For and Contribution Of Nephrectomy To Immunotherapymentioning

confidence: 99%

Immunotherapy of Metastatic Renal Cell Cancer

Fishman

Seigne

2002

Cancer Control

View full text Add to dashboard Cite

“…4 The most common symptoms are hematuria, low back pain and palpable mass, and these events occur in isolation in 35-59%, 34-41% and 30-45% of the cases, respectively. [5][6][7] The 5-year survival rate for symptomatic tumors is 30-83% while for incidental tumors it is 83-95% [8][9][10][11][12][13] and, according to tumor staging, the rate is 91% for PT1, 74% for PT2, 67% for PT3 and 32% for PT4. 14 Metastatic disease is seen in 25-40% of the cases at diagnosis, 15,16 with a 5-year survival rate of 13%.…”

Section: Introductionmentioning

confidence: 99%

Incidental and symptomatic renal tumors: impact on patient survival

et al. 2002

View full text Add to dashboard Cite

CONTEXT: Renal cell carcinoma is the third most frequent genitourinary neoplasia, and there is currently an increase in the incidental diagnosis of tumors confined to the kidneys. OBJECTIVE: To study the survival of patients with incidental and symptomatic renal tumors who have undergone nephrectomy.DESIGN: Retrospective. SETTING: Hospital Sírio Libanês and Beneficência Portuguesa de São Paulo. PARTICIPANTS: 115 patients with diagnosis of renal cell carcinoma, operated on by the same group of surgeons and evaluated by a single pathologist. MAIN MEASUREMENTS: Sex, age and diagnosis method, analyzed in two groups, according to the tumor diagnosis: Group 1 with incidental diagnosis and Group 2 with symptomatic tumors. The anatomopathological characteristics and patient survival in both groups were evaluated. A statistical analysis was performed using the Student t, chi-squared, log rank and Kaplan-Meyer tests. RESULTS: Among the studied patients, 59(51%) had an incidental diagnosis, with 78% diagnosed by ultrasonography, 20% by computerized tomography scan and 2% during surgeries; 56 patients (49%) were symptomatic. Tumor locations were equally distributed between the two kidneys, and the surgery was conservative for 24% of the incidental and 9% of the symptomatic group. In the incidental group only one patient had tumor progression and there was no death, while in the symptomatic group there were 5 progressions and 10 deaths. The 5-year specific cancer-free survival was 100% in the incidental and 80% in the symptomatic group (p = 0.001) while the disease-free rate was 98% in the incidental and 62% in the symptomatic group (p < 0001). CONCLUSION: Incidental renal tumor diagnosis offers better prognosis, providing longer disease-free survival.

show abstract

“…Treatment with standard cytotoxic chemotherapeutic agents showed disappointing efficacy with overall response rates of up to 7% and limited survival benefit [1,2,3,4]. Only immunotherapy with interferon (IFN)-α and interleukin-2 showed significant efficacy with an overall response rate of approximately 28% for combination therapy [5,6].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Temsirolimus after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer

Grundbichler¹,

Mlineritsch²,

Ressler³

et al. 2011

Oncology

View full text Add to dashboard Cite

Objective: Temsirolimus inhibits the mammalian target of rapamycin with demonstrated efficacy in patients with advanced renal cell cancer. Patients and Methods: We present a retrospective analysis of our single-center experience with temsirolimus in patients pretreated with sunitinib, sorafenib or everolimus. Sixteen patients were treated within our center starting in December 2006 until September 2009. The majority of patients (14 of 16) had received a prior antiangiogenic pretreatment. We further analyzed the efficacy of subsequent treatment with temsirolimus in these patients. Results: Stable disease could be achieved in 8 of 14 pretreated patients (57%). The duration of median progression-free survival was 10 weeks (range 1–43). Especially patients with a good response to previous antiangiogenic treatment, a good overall condition and a low Memorial Sloan Kettering Cancer Center (MSKCC) score benefited from subsequent treatment with temsirolimus. We did not see any complete or partial response meeting the World Health Organization criteria. Temsirolimus was well tolerated. Conclusion: Temsirolimus appears to be an effective and well-tolerated substance in the treatment of patients with a good performance status, low MSKCC score and stable disease under previous antiangiogenic treatment in advanced renal cell cancer. However, its use is highly questionable in pretreated patients with a poor performance score and a high MSKCC score.

show abstract

Renal Cell Carcinoma: Natural History and Results of Treatment

Cited by 172 publications

References 30 publications

Immunotherapy of Metastatic Renal Cell Cancer

Immunotherapy of Metastatic Renal Cell Cancer

Incidental and symptomatic renal tumors: impact on patient survival

Efficacy of Temsirolimus after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer

Contact Info

Product

Resources

About